Tradestie Institutional Equity Comparison Engine
AACB vs MBIO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
AACB Overall Edge
AACB Captures Institutional Edge (3โ0 Pillars ยท 6โ0 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to AACB (AACB) driven by superior Valuation, Growth & Margin, Momentum & Technical. Fundamentally, AACB trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus MBIO at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, AACB sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against MBIO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
AACB
AACB N/M vs MBIO N/M Fwd P/E
Growth & Margin Winner
AACB
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner
AACB
1Y +5.5% vs -67.4% ยท 52W Pos 98% vs 4%
Options & Structure Winner
Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
AACB
US Equity
AACB
Institutional Equity
$10.59
+0.09% 1D
Market Cap
$292.8M
1M Return
+0.86%
1Y Return
+5.48%
Forward P/E
N/M
Unified AI Score
55.3 / 100
HOLD
Tech 44.0
Fund 52.0
Flow 50.0
Mom 70.0
MBIO
NASDAQ
Mustang Bio, Inc.
Pharmaceutical Preparations
$0.39
-6.34% 1D
Market Cap
$3.2M
1M Return
+4.86%
1Y Return
-67.38%
Forward P/E
N/M
Unified AI Score
42.9 / 100
HOLD
Tech 40.0
Fund 49.0
Flow 50.0
Mom 70.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
AACB +5.48%
MBIO -67.38%
Spread: +55.68 pp (AACB Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
AACB TTM Op. Margin: 0.0%
MBIO TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AACB vs MBIO. Trailing 12-month operating profitability (AACB 0.0% vs MBIO 0.0%) and valuation multiples (AACB N/M vs MBIO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | AACB | MBIO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $292.8M | $3.2M | Larger Scale | AACB |
| Trailing P/E Ratio Valuation | 62.2x | N/M | Lower Multiple | AACB |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | +0.0% | Higher Growth | Tie |
| Operating Margin (TTM) Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | 0.0% | -43.1% | Higher ROE | AACB |
| 52-Week Range Position Momentum | 98% ($10โ$11) | 4% ($0โ$1) | Stronger Trend | AACB |
| Beta / 30D Volatility Risk Regime | 0.02ฮฒ ยท 3% Vol | 0.66ฮฒ ยท 86% Vol | Lower Realized Risk | AACB |
| Unified Institutional Score Composite Signal | 55.3 / 100 (HOLD) | 42.9 / 100 (HOLD) | Higher Composite | AACB |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full AACB vs MBIO Buy Guide
AACB
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
MBIO
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither AACB nor MBIO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.